The European Medicines Agency, the regulatory body in the EU responsible for overseeing drugs, announced today that they are declaring a formal causal link between the Johnson & Johnson COVID-19 vaccine and the blood clots that caused a pause in its rollout. (Link goes to KARE 11, a local news site. YMMV for people outside the US.) Experts in the agency say that the extremely rare and potentially fatal complication is most likely linked to the use of adenovirus as the delivery vehicle for the spike protein, and as such, is related to the AstraZeneca clotting issue, as well as putting Russia’s Sputnik vaccine and an unnamed Chinese vaccine at risk of similar problems. They recommended adding a warning to the label of the vaccine, but stressed that it is extremely rare and that the benefits of getting the shot far outweigh the potential risk.